Regulatory Inspection Section
A Regulatory Inspection section prepares for authority-led review by identifying access, records, responsible roles, communication routes, and follow-up expectations. It is distinct from a sponsor’s own independent audit.
A Regulatory Inspection section explains how the trial will support regulator access, preserve inspection-ready records, assign responsibilities, and handle inspection communications and follow-up.
Key details
Important caveats
Scope Boundary
Inspection powers and procedures depend on jurisdiction. Keep this section procedural and governance-focused rather than inventing universal regulator timelines or requirements.
Further guidance
Content
State responsible contacts, regulator access to relevant source records and essential records, site/system access arrangements, document availability, confidentiality handling, communication/escalation, and follow-up on inspection observations where applicable.
Purpose
Make the trial’s inspection-readiness responsibilities explicit without confusing regulatory inspection with sponsor monitoring or audit.
Sources and evidence
Sources are shown with the role they play in this guide. Historical or style-sensitive claims are kept within the evidence boundary described above.
- E6(R3) Good Clinical Practice Guidance for Industry — September 2025 (opens in a new tab)U.S. Food and Drug Administration · Current ICH E6(R3) GCP guidance on investigator oversight, training/delegation, participant withdrawal, investigational-product accountability, site close-out, essential records, and insurance/indemnification
- E6(R3) Good Clinical Practice (GCP) — September 2025 (opens in a new tab)U.S. Food and Drug Administration · Current FDA final-guidance overview for ICH E6(R3), including quality by design, risk-based quality management, technology, proportionality, and clarified sponsor/investigator responsibilities